多西他赛与奥沙利铂联合治疗晚期食管癌的临床疗效及安全性分析

Efficacy and Safety of Docetaxel Combined with Oxaliplatin in the Treatment of Advanced Esophageal Cancer

目的:探讨晚期食管癌经两种药物(多西他赛与奥沙利铂)联合治疗的临床疗效及不良反应发生情况。方法:将研究对象进行随机分组,分为观察组和对照组各51例,对照组采取化疗方案为多西他赛+顺铂,观察组采取化疗方案为多西他赛+奥沙利铂,比较两组临床疗效、KPS评分及不良反应发生情况。结果:总有效率在观察组与对照组之间无统计学差异(P>0.05);治疗前两组KPS评分无统计学差异(P>0.05),治疗后两组KPS评分均升高(P<0.05),且观察组KPS评分高于对照组(P<0.05);不良反应发生情况在两组之间存在统计学差异(P<0.05);血清肿瘤TSGF、CEA、CA-199水平在观察组治疗前后的降低幅度明显高于对照组(P<0.05)。结论:多西他赛与奥沙利铂联合治疗晚期食管癌的疗效确切,且不良反应少,安全性佳。

Objective:To investigate the clinical efficacy and adverse reactions of advanced esophageal cancer treated with two drugs(docetaxel and oxaliplatin).Methods:The subjects were randomly divided into the observation group(n=51)and the control group(n=51).The control group was treated with docetaxel plus cisplatin,while the observation group was treated with docetaxel plus oxaliplatin.The clinical efficacy,KPS score and the incidence of adverse reactions were compared between the two groups.Results:There was no significant difference in the total effective rate between the two groups(P>0.05).There was no significant difference in KPS scores between the two groups before treatment(P>0.05).After treatment,KPS scores of the two groups were increased(P<0.05),and KPS score of the observation group was higher than that of the control group(P<0.05).There was significant difference in the incidence of adverse reactions between the two groups(P<0.05).The reduction magnitudes of serum tumor TSGF,CEA and CA-199 levels in the observation group were significantly higher than those in the control group before and after treatment(P<0.05).Conclusion:The efficacy of docetaxel combined with oxaliplatin in the treatment of advanced esophageal cancer is accurate,with less adverse reactions and good safety.